| Q64265540 | Accumulation of Tau Protein, Metabolism and Perfusion—Application and Efficacy of Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) Imaging in the Examination of Progressive Supranuclear Palsy (PSP) and Corti |
| Q50074075 | Corticobasal degeneration: key emerging issues |
| Q64298179 | Dementia spectrum disorders: lessons learnt from decades with PET research |
| Q57175699 | Diffuse Lewy body disease manifesting as corticobasal syndrome: A rare form of Lewy body disease |
| Q58794612 | Disease-related patterns of in vivo pathology in Corticobasal syndrome |
| Q61804682 | F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes |
| Q57168250 | Imaging Protein Misfolding in the Brain Using β-Sheet Ligands |
| Q97418438 | Impairment of intermediate somatosensory function in corticobasal syndrome |
| Q50042841 | In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. |
| Q42672461 | Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case |
| Q92310096 | Recent advances in understanding frontotemporal degeneration |
| Q90407269 | Tau Imaging in Parkinsonism: What Have We Learned So Far? |
| Q91011085 | Tau PET imaging in neurodegenerative tauopathies-still a challenge |
| Q49295547 | Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms. |
| Q49900567 | Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech |
| Q57183322 | The Role of Tau Imaging in Parkinsonian Disorders |
| Q56594907 | The development and validation of tau PET tracers: current status and future directions |
| Q87934114 | [18F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation |
| Q90173686 | [18F]-AV-1451 tau PET imaging in Alzheimer's disease and suspected non-AD tauopathies using a late acquisition time window |